New drug ZW191 targets Hard-to-Treat cancers in early trial
NCT ID NCT06555744
First seen Feb 05, 2026 · Last updated Apr 29, 2026 · Updated 11 times
Summary
This early-stage study tests a new drug called ZW191 in about 145 people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to deliver a cancer-killing agent directly to cells that have a specific marker (folate receptor alpha). The main goals are to check safety and find the right dose, while also looking for signs that the drug shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
Clínica Universidad de Navarra
Madrid, 28027, Spain
-
Curie Oncology
Singapore, 217562, Singapore
-
Fundacion Instituto Valenciano de Oncologia (IVO)
Valencia, 46009, Spain
-
Gangnam Severance Hospital
Seoul, 6273, South Korea
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario Reina Sofia
Córdoba, 14004, Spain
-
Linear Clinical Research
Nedlands, WA 6009, Australia
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
NEXT Oncology Madrid
Madrid, 28223, Spain
-
NEXT Virginia
Fairfax, Virginia, 22031, United States
-
National Cancer Center
Goyang-si, 10408, South Korea
-
National Cancer Center Hospital
Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa-shi, 277-8577, Japan
-
National Cancer Centre Singapore
Singapore, 168583, Singapore
-
National University Health System (NUHS) - National University Cancer Institute Singapore (NCIS)
Singapore, 119228, Singapore
-
Royal North Shore Hospital Northern Sydney Cancer Centre
St Leonards, NSW 2065, Australia
-
Saitama Medical University International Medical Center
Saitama, 350-1298, Japan
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, 13620, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio, 43210, United States
-
The Cancer Institute Hospital of JFCR
Tokyo, 135-8550, Japan
-
Yale University
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.